IP Library Granted Patent US 10,780,241
Granted Patent B2
US 10,780,241 · App. 12/541,144 · Granted Sep 22, 2020

Devices and methods for minimizing and treating high-altitude sickness

Inventors: David Fine (Cocoa Beach, FL); Gregory Vasquez (Cocoa, FL); Bryan Johnson (Orlando, FL)
Assignee: VERO Biotech LLC
A61M16/10A61K31/198A61K33/00A61M16/021A61M16/0666A61M16/107A61M16/1075A61M2202/0208A61M2202/0275A61M2202/03A61M2205/3613
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,780,241
App. No.
12/541,144
Granted
Sep 22, 2020
Kind
B2
Abstract

A device and method for treating high-altitude sickness can include a handheld device, and can deliver a therapeutic amount of nitric oxide to an individual's lungs in order to minimize or treat high-altitude sickness. The device is self-contained and portable, which allows an individual to carry and use the device in high-altitude or other low-oxygen environments.

Claims (32)

1. An apparatus comprising:

a diffusion tube including:

a reservoir configured to contain liquid dinitrogen tetroxide (N 2 O 4 ) and having a gas space configured to be filled with gaseous nitrogen dioxide (NO 2 ) in equilibrium with the N 2 O 4 when the reservoir contains the liquid N 2 O 4 ; and

a conduit constructed of a material impermeable to the gaseous NO 2 extending into the gas space of the reservoir, the conduit defining a narrow bore capillary tube having a first end in direct contact with the gas space directly over a surface of the liquid NO 2 , a diffusion rate of the gaseous NO 2 from the diffusion tube being constant and defined by a diameter and a length of the narrow bore capillary tube if temperature remains constant;

coupled to a second end of the narrow bore capillary tube, the conversion cartridge configured to convert the gaseous NO 2 into gaseous nitric oxide (NO); and

a patient interface coupled to the conversion cartridge and configured to deliver the gaseous NO to a patient.

2. The apparatus of claim 1 , further comprising a pump in communication with the reservoir.

3. The apparatus of claim 1 , wherein the patient interface is a mouthpiece, nasal cannula, face mask, or fully-sealed face mask.

4. The apparatus of claim 1 , wherein the reservoir is in fluid communication with a source of at least one of nitrogen, air, oxygen-enriched air, or substantially pure oxygen, such that the gas space of the reservoir is configured to contain a mixture of the gaseous NO 2 and the at least one of nitrogen, air, oxygen-enriched air, or substantially pure oxygen.

5. The apparatus of claim 1 , wherein the conversion cartridge includes a surface-activated material wetted with an aqueous solution of an antioxidant.

6. The apparatus of claim 5 , wherein the surface-activated material is a silica gel.

7. The apparatus of claim 5 , wherein the antioxidant is at least one of ascorbic acid, alpha tocopherol, or aamma tocopherol.

8. The apparatus of claim 1 , wherein the patient interface is a delivery tube adapted to contact the patient's mouth or nose.

9. The apparatus of claim 1 , wherein the reservoir contains compressed nitrogen dioxide and a diluent gas.

10. The apparatus of claim 1 , wherein the conversion cartridge is configured to convert the gaseous NO 2 into the gaseous NO at a flow rate of less than 60 L/min.

11. The apparatus of claim 10 , further comprising a pump in communication with the reservoir.

12. The apparatus of claim 11 , wherein the pump is a battery-driven pump.

13. The apparatus of claim 10 , wherein the patient interface is a mouthpiece, nasal cannula, face mask, or fully-sealed face mask.

14. The apparatus of claim 10 , wherein the reservoir is in fluid communication with a source of at least one of nitrogen, air, oxygen-enriched air, or substantially pure oxygen, such that the gas space of the reservoir is configured to contain a mixture of the gaseous NO 2 and the at least one of nitrogen, air, oxygen-enriched air, or substantially pure oxygen.

15. The apparatus of claim 10 , wherein the conversion cartridge includes a surface-activated material wetted with an aqueous solution of an antioxidant.

16. The apparatus of claim 15 , wherein the surface-activated material is a silica gel.

17. The apparatus of claim 15 , wherein the antioxidant is at least one of ascorbic acid, alpha tocopherol, or gamma tocopherol.

18. Apparatus of claim 10 , wherein the reservoir contains compressed nitrogen dioxide and a diluent gas.

19. The apparatus of claim 1 , wherein the patient interface is a nasal cannula.

20. The apparatus of claim 1 , wherein the conversion cartridge includes:

at least two concentric annular particle filters; and

a surface-active material wetted with a solution of antioxidant in water.

21. The apparatus of claim 1 , wherein the conversion cartridge includes a particle filter and a surface-active material wetted with a solution of antioxidant in water cast as a solid matrix.

22. The apparatus of claim 1 , further comprising a heating element associated with the reservoir.

23. The apparatus of claim 1 , wherein the conversion cartridge is configured to convert the gaseous NO 2 into the gaseous NO at ambient temperatures.

24. The apparatus of claim 1 , wherein the conduit that defines the narrow bore capillary tube is constructed of stainless steel.

25. The apparatus of claim 1 , wherein the reservoir has a spherical shape such that the diffusion tube is configured to function at any orientation and to withstand vibration.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Aug 7, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 048173/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2009
From: FINE, DAVID H.; VASQUEZ, GREGORY; JOHNSON, BRYAN
To: GENO LLC
Reel/Frame 023430/0256 →
Continuity (2)
Provisional Application 61090617 · Aug 21, 2008
Related Publication 20100043788A1 · Feb 25, 2010
Cited By (8)
US 12,186,486 US 12,509,349 US 12,522,501 US 12,544,527 US 12,569,628 US 12,576,234 US 12,606,436 US 12,661,477